Andexxa
E852344
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Andexxa canonical | 4 |
How this entity was disambiguated
This entity first appeared as the object of triple T10291904 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Andexxa Context triple: [andexanet alfa, hasTradeName, Andexxa]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
-
C.
Auscitain
An Auscitain is a resident or native of Auch, a historic town in the Occitanie region of southwestern France.
-
D.
Plaxtol
Plaxtol is a small rural village and civil parish in Kent, England, known for its historic buildings and surrounding countryside.
-
E.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Andexxa Target entity description: Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
-
C.
Auscitain
An Auscitain is a resident or native of Auch, a historic town in the Occitanie region of southwestern France.
-
D.
Plaxtol
Plaxtol is a small rural village and civil parish in Kent, England, known for its historic buildings and surrounding countryside.
-
E.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
antidote
ⓘ
biologic drug ⓘ coagulation factor ⓘ drug ⓘ recombinant protein ⓘ reversal agent ⓘ |
| hasAdverseEffect |
infusion-related reactions
ⓘ
myocardial infarction ⓘ pneumonia ⓘ stroke ⓘ thromboembolism ⓘ urinary tract infection ⓘ |
| hasApprovalYear | 2018 ⓘ |
| hasATCCode | B02BD08 ⓘ |
| hasBlackBoxWarning |
cardiac arrest
ⓘ
ischemic events ⓘ sudden death ⓘ thromboembolic events ⓘ |
| hasContraindication | known hypersensitivity to andexanet alfa ⓘ |
| hasDosageForm |
intravenous injection
ⓘ
lyophilized powder for solution ⓘ |
| hasDrugClass |
factor Xa inhibitor reversal agent
ⓘ
hemostatic agent ⓘ |
| hasGenericName | andexanet alfa ⓘ |
| hasINN | andexanet alfa ⓘ |
| hasManufacturer |
Alexion Pharmaceuticals
ⓘ
Portola Pharmaceuticals ⓘ |
| hasMechanismOfAction |
binds factor Xa inhibitors
ⓘ
restores factor Xa activity ⓘ sequesters direct factor Xa inhibitors ⓘ |
| hasNonproprietaryName | andexanet alfa ⓘ |
| hasPharmacologicTarget |
apixaban
ⓘ
edoxaban ⓘ enoxaparin ⓘ factor Xa inhibitors ⓘ rivaroxaban ⓘ
linked to:
Xarelto
|
| hasRegulatoryStatus | prescription only ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| isAdministeredAs | intravenous bolus followed by infusion ⓘ |
| isApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| isIndicatedFor |
life-threatening bleeding
ⓘ
major bleeding associated with factor Xa inhibitors ⓘ reversal of anticoagulation ⓘ uncontrolled bleeding ⓘ |
| isModifiedFormOf | human factor Xa protein ⓘ |
| isRecombinantFormOf | human factor Xa ⓘ |
| isUsedToReverse |
apixaban
ⓘ
edoxaban ⓘ enoxaparin ⓘ rivaroxaban ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Andexxa Description of subject: Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.